<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Antiemetic dosing for adults by antineoplastic risk category&lt;SUP&gt;[1,2]&lt;/SUP&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Antiemetic dosing for adults by antineoplastic risk category<sup>[1,2]</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Antiemetic dosing for adults by antineoplastic risk category<sup>[1,2]</sup></div><div class="cntnt"><table cellspacing="0"><colgroup width="16%"></colgroup><colgroup span="3" width="28%"></colgroup> <tbody> <tr> <td class="subtitle1">Risk category</td> <td class="subtitle1">Agent</td> <td class="subtitle1">Dosing on day of chemotherapy</td> <td class="subtitle1">Dosing on subsequent days</td> </tr> <tr> <td class="divider_bottom" rowspan="18"> <p><strong>High emetic risk</strong>*<br/> (&gt;90%) </p> <p class="indent1"><strong><em>Option 1</em></strong></p> </td> <td colspan="3"><strong>NK1R antagonist (one of the following):</strong></td> </tr> <tr> <td class="indent1" rowspan="2"> <ul> <li>Aprepitant </li> </ul> </td> <td>125 mg oral</td> <td>80 mg oral daily on days 2 and 3.</td> </tr> <tr> <td>130 mg IV</td> <td> </td> </tr> <tr> <td class="indent1"> <ul> <li>Fosaprepitant </li> </ul> </td> <td>150 mg IV</td> <td> </td> </tr> <tr> <td class="indent1"> <ul> <li>Rolapitant </li> </ul> </td> <td>180 mg oral </td> <td> </td> </tr> <tr> <td class="indent1" colspan="3"><strong><em>PLUS</em></strong></td> </tr> <tr> <td colspan="3"><strong>5-HT3 antagonist (one of the following):</strong></td> </tr> <tr> <td class="indent1"> <ul> <li>Granisetron </li> </ul> </td> <td>2 mg oral; 1 mg or 0.01 mg/kg IV; 1 transdermal patch; 10 mg subcutaneous</td> <td> </td> </tr> <tr> <td class="indent1"> <ul> <li>Ondansetron </li> </ul> </td> <td>24 mg single oral dose, or 8 mg (or 0.15 mg/kg) single dose IV</td> <td> </td> </tr> <tr> <td class="indent1"> <ul> <li>Palonosetron </li> </ul> </td> <td>0.5 mg oral; 0.25 mg IV</td> <td> </td> </tr> <tr> <td class="indent1"> <ul> <li>Dolasetron </li> </ul> </td> <td>100 mg oral ONLY</td> <td> </td> </tr> <tr> <td class="indent1"> <ul> <li>Tropisetron </li> </ul> </td> <td>5 mg oral; 5 mg IV</td> <td> </td> </tr> <tr> <td class="indent1"> <ul> <li>Ramosetron </li> </ul> </td> <td>0.3 mg IV</td> <td> </td> </tr> <tr> <td class="indent1" colspan="3"><strong><em>PLUS</em></strong></td> </tr> <tr> <td colspan="3"><strong>Glucocorticoid</strong><sup>¶</sup><strong>:</strong></td> </tr> <tr> <td class="indent1"> <ul> <li>Dexamethasone </li> </ul> </td> <td>12 mg oral or IV (20 mg orally if using rolapitant)</td> <td> <p>If aprepitant is used: 8 mg oral or IV daily on days 2 to 4.<sup>Δ</sup></p> <p>If fosaprepitant is used: 8 mg oral or IV on day 2; 8 mg oral or IV twice daily on days 3 to 4.<sup>Δ</sup></p> If rolapitant is used: 8 mg oral or IV twice daily on days 2 to 4.<sup>Δ</sup></td> </tr> <tr> <td class="indent1" colspan="3"><strong><em>PLUS</em></strong></td> </tr> <tr class="divider_bottom"> <td class="indent1"> <ul> <li>Olanzapine </li> </ul> </td> <td>5 to 10 mg<sup>◊</sup></td> <td>5 to 10 mg daily on days 2 to 4.<sup>◊</sup></td> </tr> <tr> <td class="divider_bottom" rowspan="8"> <p><strong>High emetic risk</strong>*<br/> (&gt;90%) </p> <p class="indent1"><strong><em>Option 2</em></strong></p> </td> <td><strong>NEPA</strong> (netupitant plus palonosetron, capsule)</td> <td>Once</td> <td> </td> </tr> <tr> <td class="indent1" colspan="3"><strong><em>OR</em></strong></td> </tr> <tr> <td><strong>Fosnetupitant plus palonosetron</strong> (injection)</td> <td>Once</td> <td> </td> </tr> <tr> <td class="indent1" colspan="3"><strong><em>PLUS</em></strong></td> </tr> <tr> <td colspan="3"><strong>Glucocorticoid</strong><sup>¶</sup><strong>:</strong></td> </tr> <tr> <td class="indent1"> <ul> <li>Dexamethasone </li> </ul> </td> <td>12 mg oral or IV</td> <td>8 mg oral once daily on days 2 to 4 (cisplatin only<sup>§</sup>).</td> </tr> <tr> <td class="indent1" colspan="3"><strong><em>PLUS</em></strong></td> </tr> <tr class="divider_bottom"> <td class="indent1"> <ul> <li>Olanzapine </li> </ul> </td> <td>5 to 10 mg<sup>◊</sup></td> <td>5 to 10 mg daily on days 2 to 4.<sup>◊</sup></td> </tr> <tr> <td class="divider_bottom" rowspan="5"> <p><strong>Moderate emetic risk</strong><sup>¥</sup><sup>‡</sup><br/> (30 to 90%)</p> <p class="indent1"><strong><em>Non-carboplatin</em></strong></p> </td> <td colspan="3"><strong>5-HT3 antagonist (one of the following):</strong></td> </tr> <tr> <td class="indent1" colspan="3"> <ul> <li>Refer above for options for high emetic risk option 1. </li> <li>If ondansetron is used, change dose to 8 mg oral twice daily. </li> </ul> </td> </tr> <tr> <td class="indent1" colspan="3"><strong><em>PLUS</em></strong></td> </tr> <tr> <td colspan="3"><strong>Glucocorticoid:</strong></td> </tr> <tr class="divider_bottom"> <td class="indent1"> <ul> <li>Dexamethasone </li> </ul> </td> <td>8 mg oral or IV</td> <td>8 mg oral or IV daily on days 2 and 3.<sup>†</sup></td> </tr> <tr> <td class="divider_bottom" rowspan="8"> <p><strong>Moderate emetic risk</strong><sup>¥</sup><sup>‡</sup><br/> (30 to 90%)</p> <p class="indent1"><strong><em>Carboplatin based</em></strong></p> </td> <td colspan="3"><strong>NK1R antagonist (one of the following):</strong></td> </tr> <tr> <td class="indent1" colspan="3"> <ul> <li>Refer above for options for high emetic risk option 1. </li> <li>If IV aprepitant is used, the dose should be 100 mg IV on day 1, with oral aprepitant 80 mg per day on days 2 and 3, or 130 mg IV on day 1 only. </li> </ul> </td> </tr> <tr> <td class="indent1" colspan="3"><strong><em>PLUS</em></strong></td> </tr> <tr> <td colspan="3"><strong>5-HT3 antagonist (one of the following):</strong></td> </tr> <tr> <td class="indent1" colspan="3"> <ul> <li>Refer above for options for high emetic risk option 1. </li> <li>If oral ondansetron is used, change dose to 8 mg oral twice daily. </li> </ul> </td> </tr> <tr> <td class="indent1" colspan="3"><strong><em>PLUS</em></strong></td> </tr> <tr> <td colspan="3"><strong>Glucocorticoid:</strong></td> </tr> <tr class="divider_bottom"> <td class="indent1"> <ul> <li>Dexamethasone </li> </ul> </td> <td>12 mg oral or IV (20 mg orally if using rolapitant)</td> <td> </td> </tr> <tr> <td class="divider_bottom" rowspan="7"><strong>Low emetic risk</strong><br/> (10 to 30%) </td> <td colspan="3"><strong>Glucocorticoid:</strong></td> </tr> <tr> <td class="indent1"> <ul> <li>Dexamethasone </li> </ul> </td> <td>4 to 8 mg oral or IV</td> <td> </td> </tr> <tr> <td class="indent1" colspan="3"><em><strong>OR</strong></em></td> </tr> <tr> <td colspan="3"><strong>5-HT3 antagonist (one of the following):</strong></td> </tr> <tr> <td class="indent1" colspan="3"> <ul> <li>Refer above for options for high emetic risk option 1. </li> <li>If oral ondansetron is used, change dose to 8 mg oral once daily. </li> </ul> </td> </tr> <tr> <td class="indent1" colspan="3"><strong><em>OR</em></strong></td> </tr> <tr class="divider_bottom"> <td colspan="3"><strong>Phenothiazine-type drug (eg, prochlorperazine or levomepromazine)</strong></td> </tr> <tr> <td><strong>Minimal emetic risk</strong><br/> (&lt;10%) </td> <td>None</td> <td>None</td> <td>None.</td> </tr> </tbody></table></div><div class="graphic_footnotes">NK1R: neurokinin 1 receptor; IV: intravenous; 5-HT3: type 3 5-hydroxytryptamine.<br/>* Includes the combination of an anthracycline and cyclophosphamide.<br/>¶ Netupitant, aprepitant, and fosaprepitant all interfere with dexamethasone metabolism, leading to higher exposure for any specific dose. When given as a single dose on day 1, fosaprepitant impairs dexamethasone metabolism on days 1 and 2 only. If patients do not receive an NK1R antagonist, the dexamethasone dose should be adjusted to 20 mg on day 1 and 16 mg daily on days 2 to 4.<br/>Δ For patients receiving anthracycline/cyclophosphamide for breast cancer or a carboplatin-containing regimen, delete days 2 to 4 of dexamethasone.<br/><font class="lozenge">◊</font> The 5 mg dose of olanzapine is preferred for most patients receiving a cisplatin-based highly emetogenic regimen because of the likely similar efficacy and less sedation than with a 10 mg dose. There is insufficient evidence to recommend the lower dose for those receiving an anthracycline plus cyclophosphamide. <br/>§ When NEPA is used on day 1, multiday administration of glucocorticoids is only used in the delayed phase period with cisplatin. For anthracycline/cyclophosphamide combinations, administer glucocorticoids on day 1 only. If a first-generation 5-HT3 antagonist is used on day 1 rather than palonosetron, treatment with a first-generation 5-HT3 antagonist alone on days 2 and 3 is an acceptable alternative.<br/>¥ Clinicians who choose to use an NK1R antagonist for a moderate-risk regimen should follow the recommendations for high-risk chemotherapy regimens. Importantly, a corticosteroid is only given on day 1; the dexamethasone dose is lower (12 mg) unless rolapitant is employed (20 mg).<br/>‡ We would only add NK1R antagonist if carboplatin area under the curve dose is ≥4 mg/mL per min. This regimen is also appropriate for anthracycline/cyclophosphamide-containing chemotherapy in diseases other than breast cancer.<br/>† If palonosetron is the 5-HT3 receptor antagonist used on day 1, no additional prophylaxis beyond day 1 is needed for most patients.</div><div class="graphic_reference">Originally from: Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2011. Adapted and reprinted with permission. Copyright © 2011 American Society of Clinical Oncology. All rights reserved.<br/>Updated with information from:<br/><ol>
<li>​Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO Guideline Update. J Clin Oncol 2020; 38:JCO2001296.</li>
<li>Hesketh P, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2017; 35:3240.</li>
</ol></div><div id="graphicVersion">Graphic 72865 Version 32.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
